奥拉帕利维持治疗铂敏感复发性卵巢癌疗效及血清HE4、SDF-1、CA125变化分析  

Analysis of curative effect and changes of serum HE4,SDF⁃1 and CA125 in maintenance treatment of platinum⁃sensitive recurrent ovarian cancer with olaparib

作　　者：王娓娓 王芳 WANG Weiwei;WANG Fang(Department of Oncology,Huai'an Cancer Hospital,Huaian,Jiangsu,China,223200;Department of Obstetrics and Gynecology,Huai'an Cancer Hospital,Huaian,Jiangsu,China,223200)

机构地区：[1]淮安市肿瘤医院肿瘤内科,江苏淮安223200 [2]淮安市肿瘤医院妇产科,江苏淮安223200

出　　处：《分子诊断与治疗杂志》2023年第3期373-377,共5页Journal of Molecular Diagnostics and Therapy

基　　金：江苏省自然科学基金面上项目(BK20191152)。

摘　　要：目的探讨奥拉帕利维持治疗在铂敏感复发性卵巢癌患者中的应用效果及对血清人附睾蛋白4(HE4)、基质细胞衍生因子-1(SDF-1)及癌胚抗原125(CA125)的影响。方法选取淮安市肿瘤医院肿瘤内科2021年4月至2022年4月收治的108例铂敏感复发性卵巢癌患者,依照随机数字表法分为对照组和研究组,各54例,对照组患者给予铂类药物(TP)化疗,研究组在对照组基础上给予奥拉帕利维持治疗,比较两组近期疗效、血清HE4、SDF-1及CA125水平、免疫功能指标、安全性评价及治疗后半年生存质量(QoL)评分。结果治疗结束后1个月,研究组患者的ORR、DCR占比率均显著高于对照组(χ^(2)=4.216,P<0.05)。治疗结束后1个月,研究组患者血清HE4、SDF-1及CA125低于对照组(t=9.698、2.927、13.705,P<0.05)。治疗结束后1个月,研究组患者血清T淋巴细胞亚群CD3+、CD4+、NK细胞水平显著高于对照组,CD8+细胞显著低于对照组(t=6.141、8.165、8.524、14.239,P<0.05)。两组血红蛋白下降、白细胞下降、血压升高、消化道反应、呼吸困难、疲劳或乏力等不良事件发生率比较差异无统计学意义(χ^(2)=0.614,P>0.05)。研究组治疗后1个月、3个月及6个月的生存质量QoL评分均高于对照组(t=4.249、6.732、4.755,P<0.05)。结论铂敏感复发性卵巢癌患者在TP治疗的基础上应用奥拉帕利维持治疗可有效降低血清肿瘤标志物HE4、CA125及SDF-1水平,改善患者近期免疫功能,提升患者生存质量。Objective To investigate the effect of olaparib maintenance therapy in patients with platinum⁃sensitive recurrent ovarian cancer and the effect on serum human epithelial protein 4(HE4),stromal cell⁃derived factor⁃1(SDF⁃1)and carcinoembryonic antigen 125(CA125).Methods 108 patients with platinum⁃sensitive recurrent ovarian cancer admitted to the Department of Medical Oncology of Huai'an Cancer Hospital from April 2021 to April 2022 were selected and divided into a control group and a study group according to the random number table method,with 54 patients in each group.Patients in the control group were given platinum⁃based drug(TP)chemotherapy,and the study group was given olaparib maintenance therapy on the basis of the control group.The recent efficacy,serum HE4,SDF⁃1 and CA125 levels,immune function indexes,safety evaluation and quality of survival(QoL)scores at six months after treatment were compared between the two groups.Results One month after the end of treatment,the ratios of ORR and DCR in the study group were significantly higher than those in the control group(χ^(2)=4.216,P<0.05).One month after the end of treatment,serum HE4,SDF⁃1 and CA125 of patients in the study group were lower than those in the control group(t=9.698,2.927,13.705,P<0.05).One month after the end of treatment,the levels of serum T lymphocyte subsets CD3+,CD4+,and NK cells in the study group were significantly higher than those in the control group,and CD8+cells were significantly lower than those in the control group(t=6.141,8.165,8.524,14.239,P<0.05).There was no statistically significant difference in the incidence of adverse events such as decreased hemoglobin,decreased white blood cells,increased blood pressure,gastrointestinal reactions,dyspnea,fatigue or malaise between the two groups(χ^(2)=0.614,P>0.05).The survival QoL scores at one month,three months and six months after treatment in the study group were higher than those in the control group(t=4.249,6.732,4.755,P<0.05).Conclusion The application of olap

关 键 词：复发性卵巢癌 铂敏感 奥拉帕利 维持治疗 

分 类 号：R737.31[医药卫生—肿瘤]